Practical Opportunities to Improve Early Detection and Prevention of Colorectal Cancer (CRC) in Members of High-Risk Families

Digestive Diseases and Sciences

Volumn 60, Issue 3, 2015, Pages 748-761

  Patel, S G ^a   Lowery, J T ^b   Gatof, D ^c   Ahnen, D J ^c,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Gastroenterology of the Rockies   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; GENETICS; HUMAN; MASS SCREENING; PRACTICE GUIDELINE; PRIMARY PREVENTION;

ADENOMA; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION;

EID: 84940005873     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3567-2     Document Type: Review

References (76)

1. Patel S, Ahnen D. Screening for colon polyps and cancer. In: Miller AB, ed. Epidemiologic studies in cancer prevention and screening. Vol 79. New York: Springer, 2013:233–261.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117.
3. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.
4. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.
5. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–750.
6. NCCN. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening; vol. 2014. http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf, 2013.
7. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63:546–557.
8. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–1179.
9. Ait Ouakrim D, Lockett T, Boussioutas A, et al. Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis. Fam Cancer. 2013;12:459–472.
10. Rees G, Martin PR, Macrae FA. Screening participation in individuals with a family history of colorectal cancer: a review. Eur J Cancer Care (Engl). 2008;17:221–232.
11. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4:1–5.
12. Claes E, Denayer L, Evers-Kiebooms G, et al. Predictive testing for hereditary nonpolyposis colorectal cancer: subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. Genet Test. 2005;9:54–65.
13. Collins V, Meiser B, Gaff C, et al. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer. 2005;104:273–281.
14. Hadley DW, Jenkins JF, Dimond E, et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004;22:39–44.
15. Halbert CH, Lynch H, Lynch J, et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med. 2004;164:1881–1887.
16. Johnson KA, Trimbath JD, Petersen GM, et al. Impact of genetic counseling and testing on colorectal cancer screening behavior. Genet Test. 2002;6:303–306.
17. Wagner A, van Kessel I, Kriege MG, et al. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer. 2005;4:295–300.
18. Lowery JT, Marcus A, Kinney A, et al. The Family Health Promotion Project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families. Contemp Clin Trials. 2012;33:426–435.
19. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89:1406–1422.
20. Lowery JT, Horick N, Kinney AY, et al. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev. 2014;23:601–610.
21. Fletcher RH, Lobb R, Bauer MR, et al. Screening patients with a family history of colorectal cancer. J Gen Intern Med. 2007;22:508–513.
22. Kumaravel V, Heald B, Lopez R, et al. Patients do not recall important details about polyps, required for colorectal cancer prevention. Clin Gastroenterol Hepatol. 2013;11:e1–e2.
23. Brock AS, Wallace K, Romagnuolo J, et al. Patients’ short-term knowledge of personal polyp history inadequate despite systematic notification of results after polypectomy. South Med J. 2013;106:285–289.
24. Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:813–819.
25. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20:528–537.
26. Tyler CV Jr, Snyder CW. Cancer risk assessment: examining the family physician’s role. J Am Board Fam Med. 2006;19:468–477.
27. Use of electronic medical records to facilitate colorectal cancer screening in community health centers. Volume 2014: National Colorectal Cancer Roundtable; American Cancer Society; National Association of Community Health Center.
28. Kastrinos F, Allen JI, Stockwell DH, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol. 2009;104:1508–1518.
29. Kastrinos F, Steyerberg EW, Balmana J, et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut. 2013;62:272–279.
30. Khan O, Blanco A, Conrad P et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011;106:1822–1827; quiz 1828.
31. Nathanson JW, Zisman TL, Julian C, et al. Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008;42:1025–1031.
32. Klabunde CN, Vernon SW, Nadel MR, et al. Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care. 2005;43:939–944.
33. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130:1865–1871.
34. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.
35. Rex D, Schoenfeld P, Cohen J et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2015;81:31–53.
36. Austin GL, Goldstein JI, Peters SL, et al. Are colorectal cancer screening recommendations for first-degree relatives of patients with adenomas too aggressive? Clin Gastroenterol Hepatol. 2011;9:308–313.
37. Hewitt M, Greenfield S, Ellen Stovall (eds). Committee on Cancer Survivorship: Improving Care and Quality of Life, National Cancer Policy Board. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press, 2005.
38. de Vos tot Nederveen Cappel WH, Jarvinen HJ, Lynch PM, et al. Colorectal surveillance in Lynch syndrome families. Fam Cancer. 2013;12:261–265.
39. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155:69–79.
40. Lynch HT, Krush AJ. Cancer family “G” revisited: 1895–1970. Cancer. 1971;27:1505–1511.
41. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758–1762.
42. Teutsch SM, Bradley LA, Palomaki GE, et al. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med. 2009;11:3–14.
43. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–957.
44. Natarajan N, Watson P, Silva-Lopez E, et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum. 2010;53:77–82.
45. Fadhil W, Ibrahem S, Seth R, et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology. 2012;61:1117–1124.
46. Walsh MD, Buchanan DD, Pearson SA, et al. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol. 2012;25:722–730.
47. Yurgelun MB, Goel A, Hornick JL, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila). 2012;5:574–582.
48. Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009;11:238–247.
49. Meijer TW, Hoogerbrugge N, Nagengast FM, et al. In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology. 2009;55:414–422.
50. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.
51. Wei EK, Colditz GA, Giovannucci EL, et al. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses’ Health Study. Am J Epidemiol. 2009;170:863–872.
52. Colorectal Cancer 2011 Report. Volume 2014: World cancer research fund global network, 2011.
53. Von Karsa L, Anttila A, Ronco G et al. Cancer screening in the European Union, report on the implementation of the council recommendation on cancer screening—first report. In: Cancer. IAfRo, ed. Luxembourg: European Commission, 2008.
54. USPSTF. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–637.
55. Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. In: Australian National Health & Medical Research Council; Cancer Council Australia ACN, ed, 2005.
56. Ranger GS. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 2014;34:6277–6282.
57. Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol. 2011;25:607–622.
58. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884.
59. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.
60. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–1682.
61. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–1764.
62. Arber N, Spicak J, Racz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011;106:1135–1146.
63. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009;2:310–321.
64. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin N Am. 2002;82:905–941.
65. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–266.
66. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527.
67. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750.
68. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–1606.
69. Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol. 2012;13:1242–1249.
70. Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum. 1993;36:84–90.
71. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108–1115.
72. Force USPST. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–364.
73. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S–e668S.
74. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol Ann Oncol. 2014;2015:47–57.
75. Ritov I, Baron J. Reluctance to vaccinate: omission bias and ambiguity. J Behav Decis Mak. 1990;3:263–277.
76. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342:1960–1968.